OncoCell MDx Appoints Marc Stapley to its Board of Directors

ROYAL OAK, Mich.–(BUSINESS WIRE)–#OncoCellMDx–OncoCell MDx, an immunogenomics platform company developing novel, noninvasive molecular diagnostic assays for cancer and other disease, today announced that Marc Stapley has joined the company’s Board of Directors.


“I am excited to have Marc Stapley join the OncoCell Board of Directors. Marc brings a wealth of relevant experience as an executive and a board member to our team, including a track record of growing and transforming companies in the genomics and molecular Dx space. We look forward to benefiting from his strategic insight and to leveraging his capabilities,” said Harry Stylli, Ph.D., founder and executive chairman of OncoCell MDx. “The OncoCell transformative immunogenomics platform enables us to leverage the power of immune cells to develop a portfolio of compelling noninvasive molecular diagnostics tests for a range of diseases. Our first test to market will be a novel, noninvasive assay for prostate cancer.”

“Marc is someone I respect greatly. He brings additional strategic vision and understanding of the diagnostic space to our boardroom. I’m looking forward to working with and learning from him as we continue to build a transformative company,” said Mark McDonough, President and CEO of OncoCell MDx.

Stapley is President and CEO of genomics company Helix and a member of the Glaukos Board of Directors. He previously served as executive vice president at Illumina, where he was responsible for corporate strategy, business development and population genomics. During his seven years at Illumina, Stapley also served as the chief administrative officer, responsible for finance, business development, legal, human resources, IT, facilities and government affairs, and as chief financial officer. Prior to Illumina, he held executive finance positions at Pfizer and other large multinational companies.

“With its innovative technology platform and experienced team, OncoCell has a tremendous opportunity to transform the diagnosis and management of prostate cancer and other disease,” said Stapley. “I look forward to serving as a member of OncoCell’s board of directors and to contributing to the company’s growth and success.”

About OncoCell MDx:

OncoCell MDx is a privately held company developing and commercializing novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School by OncoCell MDx’s co-founder, Professor Amin I. Kassis. The company’s noninvasive blood-based immunogenomic assays are designed to aid physicians to better understand underlying disease pathology in prostate cancer and other oncology and non-oncology indications. For more information about OncoCell MDx and its technology, visit: https://oncocellmdx.com/.

Contacts

Virginia Amann for OncoCell MDx

VirginiaAmann@ENTENTEInc.com

M: +1.608.207.0082 (preferred)

O: +1.312.416.8438

error: Content is protected !!